- Home
- MFC vs CRNX Comparison
MFC vs CRNX Comparison
Compare MFC & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFC
- CRNX
- Stock Information
- Founded
- MFC 1887
- CRNX 2008
- Country
- MFC Canada
- CRNX United States
- Employees
- MFC N/A
- CRNX N/A
- Industry
- MFC Life Insurance
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- MFC Finance
- CRNX Health Care
- Exchange
- MFC Nasdaq
- CRNX Nasdaq
- Market Cap
- MFC 51.7B
- CRNX 2.8B
- IPO Year
- MFC 1999
- CRNX 2018
- Fundamental
- Price
- MFC $31.47
- CRNX $35.52
- Analyst Decision
- MFC Buy
- CRNX Strong Buy
- Analyst Count
- MFC 1
- CRNX 7
- Target Price
- MFC $49.00
- CRNX $74.33
- AVG Volume (30 Days)
- MFC 1.8M
- CRNX 1.1M
- Earning Date
- MFC 11-05-2025
- CRNX 11-11-2025
- Dividend Yield
- MFC 3.93%
- CRNX N/A
- EPS Growth
- MFC 33.03
- CRNX N/A
- EPS
- MFC 2.29
- CRNX N/A
- Revenue
- MFC $22,915,108,577.00
- CRNX $1,392,000.00
- Revenue This Year
- MFC $34.27
- CRNX $489.51
- Revenue Next Year
- MFC $8.25
- CRNX $661.93
- P/E Ratio
- MFC $13.61
- CRNX N/A
- Revenue Growth
- MFC 9.72
- CRNX 0.51
- 52 Week Low
- MFC $25.92
- CRNX $24.10
- 52 Week High
- MFC $33.07
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- MFC 55.49
- CRNX 63.30
- Support Level
- MFC $30.86
- CRNX $33.42
- Resistance Level
- MFC $32.35
- CRNX $37.23
- Average True Range (ATR)
- MFC 0.48
- CRNX 1.48
- MACD
- MFC 0.08
- CRNX 0.03
- Stochastic Oscillator
- MFC 59.53
- CRNX 76.36
About MFC Manulife Financial Corporation
Manulife Financial is one of the Big Three Canadian life insurers. The firm provides life insurance, annuities, and asset management products to individuals and group customers in Canada, the United States, and Asia. The Canadian business segment contributes approximately 22% of adjusted earnings. The Asia segment operates across 12 countries and contributes around 36% of earnings, with a significant presence in Hong Kong and Singapore. The US business, which primarily operates under the John Hancock brand, contributes about 23% of earnings and is one of the top 20 life insurers in the US. Manulife's global asset and wealth management business contributes approximately 20% of its earnings and had around CAD 1.03 trillion in assets under management and administration as of the end of 2024.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.